New Intelligence Products for the Analysis of Prostate Cancer Therapeutics
(PRWEB) October 11, 2004
A range of products covering this dynamic field have now been released, together covering the range of information needs of all categories of customers, from those with limited knowledge of the field to those with substantial knowledge. Save time and money using BioSeeker Group’s informative structure and unbiased analysis to improve your own business intelligence and maintain the momentum in your business.
Products in prostate cancer therapeutics:
Business Development and R&D Database: Prostate Cancer
Global Structure of Prostate Cancer R&D
Basic Platform Report: Prostate Cancer
Prostate Cancer: New Guidelines and R&D progress
Analytical Tool: Prostate Cancer
Increased possibilities to diagnose prostate cancer at an earlier stage, will dramatically increase the market size for drugs targeting this disease. This fact in turn will increase the possibilities to find business opportunities. This has already been realized by many and made the field of prostate cancer therapeutics a highly competitive area.
The year 2004 has been a year of change. First of all, the American Society of Clinical Oncology (ASCO) released a new guideline for treating men with androgen-sensitive prostate cancer in June. Secondly, Taxotere injection concentrate in combination with prednisone is moving forth as a treatment for advanced prostate cancer, which is no longer responding to hormonal therapy.
The conclusions made by the ASCO expert panel on androgen deprivation therapy (ADT) is that the use of nonsteroidal anti-androgens can be viewed as an alternative to orchiectomy or drug treatment with luteinizing hormone releasing hormone agonists (medical castration).
Since no studies have satisfactory demonstrated a survival advantage for starting treatment earlier, the panel feels that no specific recommendations can be issued regarding the question of early versus deferred ADT. Researchers involved in the Early Prostate Cancer program have concluded that hormone therapy initiated immediately following initial therapy reduces the risk of cancer progression. For men with localized or locally advanced prostate cancer treated with initial radiation therapy, immediate hormone therapy also improves progression-free survival.
BioSeeker Group has identified, structured and analyzed most of the activities related to prostate cancer therapeutics. Take advantage of this and invest in our unique products.
For more information about this report, please visit BioSeeker’s website.
###